Merck Sharp and Dohme to share new drug data at ECCMID 2017

Merck Sharp and Dohme will be attending this year's European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), where it will share its latest scientific insights in this field.

Researchers from the company will provide more than 25 scientific data presentations on established and investigational infectious disease medicines at ECCMID 2017, which runs from April 22nd to 25th in Vienna.

These will include a topline data presentation from a pivotal phase III clinical study of the cytomegalovirus therapy letermovir and real-world use findings about the performance of Zerbaxa, which is indicated for the treatment of adults with complicated urinary tract infections. 

Other studies to be presented include data on the in vitro activity of the investigational beta-lactamase inhibitor relebactam, collected as part of the SMART surveillance programme initiated in 2002.

Dr Nicholas Kartsonis, vice-president for infectious disease clinical research at Merck Research Laboratories, said: "Infectious diseases remain one of the great public health threats in the world today. At Merck, we have never wavered in our commitment to invest in developing anti-infective therapies that prevent and treat serious infectious diseases."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.